Last updated: February 27, 2026
What Is NDC 24208-0635?
NDC 24208-0635 is a medication identified by the National Drug Code (NDC). According to the Food and Drug Administration (FDA), this code corresponds to Saxenda (liraglutide) Injection, 3 mg. It is a prescription medication approved for chronic weight management in adults with obesity or overweight with comorbidities.
Current Market Landscape
Product Overview
| Attribute |
Details |
| Manufacturer |
Novo Nordisk |
| Formulation |
Subcutaneous injection, 3 mg |
| Approved Uses |
Weight management, obesity treatment |
Key Competitors
| Drug Name |
Active Ingredient |
Approval Year |
Typical Indications |
| Wegovy |
Semaglutide |
2021 |
Obesity, weight management |
| Contrave |
Bupropion/Naltrexone |
2014 |
Obesity, weight loss |
| Phentermine |
Phentermine Hydrochloride |
1959 |
Short-term weight loss |
Market Size & Growth
- The global obesity drugs market reached approximately USD 4.4 billion in 2022, with an annual growth rate of 15% predicted through 2028 (Research and Markets, 2022).
- The North American market holds about 65% of this revenue, driven by high obesity prevalence and healthcare spending.
Prescription Trends
- In 2022, Saxenda saw approximately 700,000 prescriptions in the U.S.
- Wegovy's prescriptions exceeded 500,000 in the same period, reflecting aggressive market uptake.
Regulatory and Reimbursement Landscape
- FDA approval: 2014 for Saxenda; expanded approval for Wegovy in 2021.
- Insurers: Coverage varies; commercial insurers increasingly reimburse GLP-1 receptor agonists owing to efficacy and obesity-related comorbidity management.
- Pricing: List price for Saxenda is around USD 1,350 per month; Wegovy is approximately USD 1,350 per month as well (GoodRx, 2023).
Price Projections and Market Dynamics
Short-term (Next 1 Year)
| Scenario |
Price Range |
Drivers |
Notes |
| Stable |
USD 1,300–1,400 |
Current demand, manufacturer pricing |
Slight fluctuations based on discounting |
| Slight decrease |
USD 1,200–1,300 |
Increased competition from Wegovy |
Suppliers offering rebates and discounts |
Medium-term (1–3 Years)
| Scenario |
Price Range |
Drivers |
Notes |
| Price reduction |
USD 1,100–1,200 |
Entry of biosimilars, increased competition |
Biosimilar development unlikely soon for liraglutide |
| Price stability |
USD 1,200–1,300 |
Established market share, exclusivity |
Price supports premium positioning |
Long-term (Beyond 3 Years)
| Scenario |
Price Range |
Drivers |
Notes |
| Price decline |
USD 800–1,000 |
Patent expiration, biosimilars |
Price erosion expected after patent expiry (approx. 2030) |
| Price stabilization |
USD 1,200 |
Brand loyalty, clinical efficacy |
Extended patent life or new formulations possible |
Market Drivers and Risks
- rising prevalence of obesity increases demand.
- regulatory pressure to lower drug prices.
- evolving insurance reimbursement policies.
- development of biosimilars and generics.
- clinical trial results favoring newer or alternative therapies.
Key Market Entry and Pricing Strategies
- Premium positioning for brand differentiation.
- Rebate programs to improve formulary access.
- Tiered pricing based on geographic markets.
- Partnerships with payers for coverage expansion.
Final Analysis
NDC 24208-0635, Saxenda, faces stiff competition from Wegovy and other weight-loss therapies. Market growth remains robust, supported by increasing obesity rates and favorable regulatory trends. Price projections indicate modest reductions in the short term with significant declines after patent expiration unless new formulations or indications are developed.
Key Takeaways
- The current list price for Saxenda hovers around USD 1,350/month.
- Market projections forecast prices to slightly decrease over the next 1–3 years due to competition.
- Long-term price declines are likely post-patent expiry, expected around 2030.
- The obesity pharmacotherapy market is growing rapidly, with a focus on GLP-1 receptor agonists.
- Reimbursement and formulary placement significantly influence pricing trajectories.
FAQs
1. What is the primary driver of price stability for NDC 24208-0635?
Brand loyalty and proven clinical efficacy support maintaining current pricing levels.
2. How does the entry of Wegovy impact Saxenda's market price?
It potentially leads to price competition, rebates, and discounts to retain market share.
3. When is patent expiry expected for Saxenda?
Approximately in 2030, unless new patent filings or formulations extend exclusivity.
4. Are biosimilars of liraglutide likely to impact prices soon?
Biosimilars for liraglutide are under development, but market entry is unlikely within the next few years due to regulatory and development timelines.
5. What are the primary factors affecting long-term pricing of NDC 24208-0635?
Patent expiration, biosimilar development, regulatory changes, and healthcare coverage policies.
References
- Research and Markets. (2022). Global Obesity Drugs Market Report.
- GoodRx. (2023). Saxenda Pricing & Coupons.
- FDA. (2014). Approval of Saxenda for Weight Management.
- FDA. (2021). Approval of Wegovy for Obesity.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement Policies for Obesity Treatments.
